Phase 3 TOURMALINE-MM2 trial

Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma

Osaka, Japan & Cambridge, Mass., United States:  Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3…

Read More »